Patent intelligence · US
US 10034919
Targeted human-interferon fusion proteins
Targeted human-interferon fusion proteins
Patent details — US 10034919
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 31, 2018
- Expiration
- Jul 26, 2038
- Applicant
- Universite Montepellier 2
- Claims
- 12
- CPC classes
- A61K, A61K38/212, A61K47/6813, A61P
Quick answer
US 10034919 (Targeted human-interferon fusion proteins) is held by Universite Montepellier 2. Status: granted. Granted Jul 31, 2018. Expires Jul 26, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Universite Montepellier 2
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K38/212, A61K47/6813, A61P, A61P19/00, A61P31/12
More from Universite Montepellier 2
Related pharmaceutical patents in our USPTO index.
-
US 12391663
Isoindolinone compounds
granted -
US 12378199
Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules
granted -
US 12280029
Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
granted -
US 12263143
Ionic channel modulation as a method for treating tumors through inflammasome activation
granted -
US 12257247
Targeted degradation of VAV1
granted -
US 12214218
Perfusion modulated tumor dose sculpting with single dose radiotherapy
granted -
US 12070628
Low energy immune priming for treating cancer and metastasis
granted -
US 12011619
Low intensity focused ultrasound for treating cancer and metastasis
granted
Frequently asked questions
What is US patent 10034919?
US 10034919 (Targeted human-interferon fusion proteins) is held by Universite Montepellier 2. Status: granted. Granted Jul 31, 2018. Expires Jul 26, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10034919?
Universite Montepellier 2 is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 10034919 expire?
Our index shows an expiration date of Jul 26, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.